Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$9.477M
TTM
Current Assets
$2.625M
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
269.78%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$1.652M
Q3 2024
Cash
Q3 2024
P/E
-0.3791
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Selling, General & Admin $4.179M $5.345M $2.484M $2.350M $3.070M $4.120M $3.620M $1.000M $880.0K
YoY Change -21.81% 115.18% 5.7% -23.45% -25.49% 13.81% 262.0% 13.64%
% of Gross Profit
Research & Development $6.131M $2.698M $1.254M $2.866M $23.19M $17.70M $6.698M $1.331M $3.960M
YoY Change 127.24% 115.15% -56.25% -87.64% 31.05% 164.2% 403.23% -66.39%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.131M $2.698M $1.254M $2.866M $26.27M $17.70M $6.698M $1.331M $4.840M
YoY Change 127.24% 115.15% -56.25% -89.09% 48.45% 164.2% 403.23% -72.5%
Operating Profit -$14.54M -$8.043M -$3.738M -$5.213M -$21.82M -$11.42M -$2.377M
YoY Change 80.78% 115.17% -28.29% 91.02% 380.48%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Interest Expense -$206.0K $4.440M $7.000K $60.00K $360.0K $0.00 $294.0K $420.0K -$380.0K
YoY Change -104.64% 63328.57% -88.33% -83.33% -100.0% -30.0% -210.53%
% of Operating Profit
Other Income/Expense, Net $4.258M $5.580M $0.00 $175.0K $0.00 -$70.00K
YoY Change -23.69% -100.0% -100.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Pretax Income -$10.49M -$3.603M -$3.731M -$5.150M -$25.91M -$21.55M -$12.26M -$3.180M -$5.230M
YoY Change 191.09% -3.43% -27.55% -80.12% 20.23% 75.77% 285.53% -39.2%
Income Tax $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.49M -$3.552M -$3.731M -$5.151M -$25.91M -$21.55M -$12.26M -$3.177M -$5.230M
YoY Change 195.27% -4.8% -27.57% -80.12% 20.24% 75.79% 285.84% -39.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.98 -$1.63 -$0.22 -$0.31
Diluted Earnings Per Share -$0.98 -$1.63 -$0.22 -$0.31 -$1.648M -$2.104M -$1.849M -$381.3K -$627.1K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Cash & Short-Term Investments $1.783M $6.708M $3.763M $3.130M $8.750M $2.670M $21.78M $200.0K $10.00K
YoY Change -73.42% 78.26% 20.22% -64.23% 227.72% -87.74% 10790.0% 1900.0%
Cash & Equivalents $1.783M $6.708M $3.763M $3.130M $8.750M $2.670M $11.78M $200.0K $10.00K
Short-Term Investments $0.00 $10.00M
Other Short-Term Assets $67.00K $137.0K $107.0K $110.0K $170.0K $1.850M $390.0K $0.00 $0.00
YoY Change -51.09% 28.04% -2.73% -35.29% -90.81% 374.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.850M $6.845M $3.960M $3.250M $8.920M $4.530M $22.17M $200.0K $10.00K
YoY Change -72.97% 72.85% 21.85% -63.57% 96.91% -79.57% 10985.0% 1900.0%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Total Assets $1.850M $6.845M $3.960M $3.250M $8.920M $4.530M $22.17M $200.0K $10.00K
YoY Change
Accounts Payable $78.00K $337.0K $304.0K $140.0K $350.0K $3.090M $2.740M $510.0K $490.0K
YoY Change -76.85% 10.86% 117.14% -60.0% -88.67% 12.77% 437.25% 4.08%
Accrued Expenses $532.0K $633.0K $205.0K $740.0K $760.0K $2.070M $50.00K $1.750M $680.0K
YoY Change -15.96% 208.78% -72.3% -2.63% -63.29% 4040.0% -97.14% 157.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $3.850M $1.170M
YoY Change -100.0% 229.06%
Total Short-Term Liabilities $1.196M $3.579M $509.0K $890.0K $2.120M $5.160M $2.790M $6.420M $2.450M
YoY Change -66.58% 603.14% -42.81% -58.02% -58.91% 84.95% -56.54% 162.04%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $2.030M $2.700M
YoY Change -100.0% -24.81%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $2.030M $2.700M
YoY Change -100.0% -24.81%
Total Liabilities $268.0K $2.940M $509.0K $890.0K $2.120M $5.160M $2.790M $8.450M $5.150M
YoY Change -90.88% 477.6% -42.81% -58.02% -58.91% 84.95% -66.98% 64.08%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Basic Shares Outstanding 10.59M 2.185M 17.00M 16.51M
Diluted Shares Outstanding 2.185M 17.00M 16.51M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $3.5929 Million

About AVENUE THERAPEUTICS, INC.

Avenue Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Bay Harbor Islands, Florida and currently employs 3 full-time employees. The company went IPO on 2017-06-27. Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The firm is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.

Industry: Pharmaceutical Preparations Peers: Dermata Therapeutics, Inc. Evoke Pharma Inc Grapefruit USA, Inc JOHNSON & JOHNSON NovaBay Pharmaceuticals, Inc. Sonoma Pharmaceuticals, Inc. SenesTech, Inc. Stem Holdings, Inc.